Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice article in Allure, referencing Harvard scientists and their work on NAD.
Insiders already hold 36% of the shares.
Your foresight in buying the stock will be rewarded. There are numerous catalysts for increased share value coming. The continuing short attack is both unnerving and frustrating but it does not reflect the value of the stock. You are not losing anything unless you sell.
Been accumulating at these prices too! Why wouldn't you.
thanks Karin for your article - Great News to see that P&G have submitted a number of patents for their potential 'Niagen' products. Have been looking for news on this as it has been over a year since the agreement was signed.
I see the short attack continues. I, for one, have put a sell order for a couple times the current price to prevent the shorts from using my shares. At least I am not aiding their efforts.
I see the short attack continues. I, for one, have put a sell order for a couples times the current price to prevent the shorts from using my shares. At least I am not aiding their efforts.
I have been taking it for awhile. Trying to be objective as I can, I do believe I am benefiting. AT 66 I am probably a prime candidate most likely with good reason. I am in good health at a good weight but the niagen does seem to provide an extra 'spark'. Hard to prove, but that is what the human trials are all about. I applaud CDXC for undertaking them and look forward to the results. Good results if my own experience is any indication.
Short Attack - Sound familiar?
How it works
This process can be used by hedge funds to either pump up a stock or to trash a stock but since I am using ****** as an example, we will discuss that situation. First information is widely distributed to make investors wonder about the company and to put fear into those longs that hold the stock. Next, high volume shorting takes place to drive the company's share price down.
As the short attack continues, more people parade out news to continue to put questions in the back of investors' minds. On a daily basis, shorts use computerized trading to control the direction of the share price. At opportune times, the shorts overwhelm the buyers (bid price) of the stock by selling short large number of shares to drive the share price down and to eliminate the buyers for the stock at that given time. For people who are not familiar with the bid/ask process of trading stocks, here is a link to explain that process.
Shorts need to control the stock's share price over a long time (often several months to well over a year), and can't afford to just accumulate an unlimited number of short positions in the stock, so they have to be buying shares at the same time they are selling shares too. When the shorts drive the share price down, eliminating buyers as discussed above, some of those investors trying to sell their shares at that same time will follow the share price activity downward lowering their ask price.
Now the shorts can buy back some of the shares they have shorted at lower prices including some shares where longs have put stop-loss sale orders to protect against downside losses. The shorts will only buy shares part of the way back up as the share price rises, and then wait to see if new buyers come into the market. If the share price continues to rise up to much again during the day, the shorts will repeat the same selling and buying process to control the share price.
As mentioned above, the shorts need to control the share price over an extended period of time. They need to wear down the longs with rumor mongering as well as by creating fear as the longs continue to see the share price go down from the computerized trading. They hope the longs will give up and sell their shares at the lowest possible share price.
Another observation, shorts try to wear down the longs by making sure that the share price closes down as many days in a row as they can put together. At the close of each day, I witnessed volume dramatically increasing as the shorts tried to insure Herbalife's share price closed down. Shorts are hoping the longs frustration with the share price continuing downward will end up in capitulation where as many longs as possible just give up and sell their shares.
I don't know how low the shorts will drive the share price of Herbalife during this current short attack, but I do believe Herbalife is a strong good growing company. As with all false short attacks, the share price will bounce back. After the share price bottom is reached, I expect the shorts to continue their rumor mongering so they can continue buying to cover their shorts as the share price rises back up.
The short attack never ended. The number of shares shorted in June remains about the same as now. The stock is being manipulated. News or fundamentals are not driving it down. Aggravating and frustrating to be sure, but the potential remains considerable.
The shorts, who seem to have a fairly large position, appear to be playing with the stock in the absence of news and prior to earnings. It's not the first time the stock has floated down like this. Exceedingly frustrating but as a long term holder I reckon patience will win out quite nicely.
The Bleecker Street article has been pulled -
"This article has been removed from the site. The below is a message from the author.
Bleecker Street Research is removing its article on Barry Honig, ChromaDex, and Pershing Gold. After further research we believe that the statements were not supported and the premise of the article was allegedly factually inaccurate. Bleecker Street would like to apologize to ChromaDex, Pershing Gold, and Barry Honig for an allegedly misleading article and to immediately set the record straight for our readers who should not rely on certain aspects upon the withdrawn article or statements of the author therein. To our readers: In the future we will document everything even more carefully."
The ratbags are undoubtedley profiting by buying cheap after shorting.
Chromodex responds in more detail to the false short attack allegations:
New Shareholder Letter
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-irhome
Been a stockholder for a number of years, sometimes frustrating but ultimately it has become a favourite stock of mine and when looking at the future find it difficult to see why anyone would sell at the current price! Apart from the reasons stated. I too might add to my largish position especially as events appear to be lining up to give outstanding returns. Good luck with your timing - I never seem to get it right!
ChromaDex Lead Ingredient NIAGEN® Nicotinamide Riboside Receives New Dietary Ingredient (NDI) Status From the FDA
IRVINE, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today it has received New Dietary Ingredient (NDI) status from the FDA for its patented and proprietary lead ingredient, NIAGEN® nicotinamide riboside.
ChromaDex's NIAGEN® is the first and only commercially available form of nicotinamide riboside NR and is supported by five patents issued and several pending, with patents rights acquired from Dartmouth College, Cornell University, and Washington University.
The Federal Food, Drug, and Cosmetic Act (the FD&C Act) requires that manufacturers and distributors who wish to market dietary supplements that contain "new dietary ingredients" notify the Food and Drug Administration about these ingredients. Generally, the notification must include information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing a new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. (See Section 413(d) of the FD&C Act, 21 U.S.C. 350b(d)).
Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “Receiving NDI status from the FDA validates the safety dossier we have compiled for NIAGEN®. Achieving NDI status is a significant milestone given that the FDA objected approximately 88% of NDI notifications in FY 2014. NDI status opens the door for the mainstream commercialization of NIAGEN® in dietary supplements.”
In August 2015, ChromaDex announced results from the first human clinical study which demonstrated that single doses of NIAGEN® nicotinamide riboside can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold and is safe.
ChromaDex Reports 6th Consecutive Quarter of Record Revenue as Q3 Ingredients Sales Climb 104%
By GlobeNewswire, November 12, 2015, 04:10:00 PM EDT
Vote up AAA
- Public Company Reaches GAAP Break-Even as 3rd Quarter Revenue Grows 52% to a Record $6.3 Million -
IRVINE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients that creates science-based solutions for dietary supplements, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today record revenue for the third quarter ended October 3, 2015. The report marks the sixth consecutive quarter of record revenue for the Company.
- Results of operations for the three months ended October 3, 2015 -
For the three months ended October 3, 2015 ("Q3 2015"), ChromaDex reported record net sales of $6.3 million, an increase of 52% as compared to $4.1 million for the three months ended September 27, 2014 ("Q3 2014"). This increase was largely due to increased sales in its ingredients business segment, driven by its lead ingredient, NIAGEN® branded nicotinamide riboside. The ingredients segment generated record net sales of $4.1 million for Q3 2015, an increase of 104%, compared to $2.0 million for Q3 2014, and a sequential increase of 22% as compared to Q2 2015.
The core standards and services segment posted sales of $1.9 million for Q3 2015, an increase of 3% as compared to $1.8 million for Q3 2014. Net sales for the scientific and regulatory consulting segment were $265K, a decrease of 10% as compared to $294K for Q3 2014.
The net loss attributable to common stock holders for Q3 2015 was $4K or ($0.00) per share as compared to a net loss of $660K or ($0.01) per share for Q3 2014. This marks the first quarter ChromaDex has moved close to GAAP breakeven since the first quarter of 2010.
Adjusted EBITDA for Q3 2015 was $695K, compared to Adjusted EBITDA of ($152K) for Q3 2014. ChromaDex defines Adjusted EBITDA as net income (loss) adjusted for income tax, interest, depreciation, amortization and non-cash stock compensation costs. The Basic and Diluted Adjusted EBITDA per share for Q3 2015 was $0.01 versus ($0.00) for Q3 2014.
Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "Our 6th consecutive quarter of record revenue has led to improved overall financial performance, as we have moved to a GAAP break-even as well as posted $695K of Adjusted EBITDA. The financial performance starts to illustrate the scale and earnings leverage in our business model."
Read more: http://www.nasdaq.com/press-release/chromadex-reports-6th-consecutive-quarter-of-record-revenue-as-q3-ingredients-sales-climb-104-20151112-01258#ixzz3rMUaycVf
Life extension, HPN(amazon)
Niagem Study Initial Results
ChromaDex Corp. (OTCQX: CDXC) announced today that the initial results of the first human clinical study for the company's NIAGEN® nicotinamide riboside (NR) has met its primary endpoint. The results demonstrated that a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+) in healthy human volunteers. The study shows for the first time a similar conversion of NR into NAD+ as has been shown in prior animal studies.
Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function. If NAD+ levels go down or are redirected (as in cancer cells), mitochondrial function erodes, creating numerous adverse effects. For example, results of a mouse study conducted by the National Institutes of Health (NIH) in collaboration with ChromaDex published in November 2014 indicated that NR was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated aging disease known as Cockayne Syndrome (CS). The researchers concluded that NR showed promise as a potential therapy for the disease, as well as for other age-related neurodegenerative conditions.
In the first human clinical study of NIAGEN®, NAD+ metabolomic analyses were completed in blood for various time points over a 24-hour period. For the first time, the study also established an effective dose range for NR in humans.
A preliminary analysis of the results did not reveal any safety issues with NR, which is consistent with previous safety results demonstrated in numerous cell and animal studies.
The full results of the study will be submitted for peer review in the scientific literature.